Asset Details
Do you wish to reserve the book?
A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga-DOTATATE
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga-DOTATATE
Do you wish to request the book?
A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga-DOTATATE
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga-DOTATATE
2022
Overview
Purpose
The purpose of this study is to evaluate the diagnostic efficacy of
68
Ga-NODAGA-LM3 and
68
Ga-DOTA-LM3 and compare them with
68
Ga-DOTATATE in patients with well-differentiated neuroendocrine tumors.
Methods
Patients were prospectively recruited and equally randomized into two arms: Arm A, patients would undergo a whole-body
68
Ga-NODAGA-LM3 PET/CT scan on the 1st day and
68
Ga-DOTATATE PET/CT scan on the 2nd day; Arm B, patients would undergo a whole-body
68
Ga-DOTA-LM3 PET/CT scan on the 1st day and
68
Ga-DOTATATE PET/CT scan on the 2nd day. Biodistribution in normal organs, lesion detection ability, and tumor uptake were compared between antagonist and agonist in each arm.
Results
A total of 40 patients with well-differentiated NETs, 20 in each arm, were recruited in the study.
68
Ga-NODAGA-LM3 showed a similar pattern as
68
Ga-DOTATATE, while
68
Ga-DOTA-LM3 demonstrated significantly lower uptake in almost all normal organs compared to
68
Ga-DOTATATE. Both
68
Ga-NODAGA-LM3 and
68
Ga-DOTA-LM3 showed superiority in lesion detection compared to
68
Ga-DOTATATE on lesion-based and patient-based comparison.
68
Ga-NODAGA-LM3 showed a significantly higher tumor uptake (median SUVmax 29.1 versus 21.6,
P
< 0.05) and tumor-to-background ratio (median tumor-to-liver ratio 5.0 versus 2.9,
P
< 0.05) compared to
68
Ga-DOTATATE.
68
Ga-DOTA-LM3 showed comparable uptake (median SUVmax 16.1 versus 17.8,
P
= 0.714) and higher tumor-to-background ratio (median tumor-to-liver ratio 5.2 versus 2.1,
P
< 0.05).
Conclusion
Both
68
Ga-NODAGA-LM3 and
68
Ga-DOTA-LM3 are promising SSTR2 antagonists for neuroendocrine tumors. They demonstrated superiority in diagnostic efficacy compared to agonist
68
Ga-DOTATATE.
Trial registration
ClinicalTrials.gov identifier: NCT04318561
We currently cannot retrieve any items related to this title. Kindly check back at a later time.